Clinical Trials
7
Active:0
Completed:3
Trial Phases
2 Phases
Phase 1:6
Not Applicable:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
6 (85.7%)Not Applicable
1 (14.3%)Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
Not Applicable
Recruiting
- Conditions
- Cutaneous Lupus Erythematosus
- Interventions
- Drug: SOF-SKN 0.25%Drug: SOF-SKN 0.5%Drug: SOF-SKN 1%Drug: SOF-SKN 2%Drug: Placebo
- First Posted Date
- 2025-07-18
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 32
- Registration Number
- NCT07072611
- Locations
- 🇦🇺
Doherty Clinical Trials, Melbourne, Victoria, Australia
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
- First Posted Date
- 2021-10-29
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 9
- Registration Number
- NCT05100628
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Mayo Clinic Florida - Oncology, Jacksonville, Florida, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
Phase 1
Terminated
- Conditions
- Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors
- Interventions
- Radiation: EBRT
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 21
- Registration Number
- NCT04957290
- Locations
- 🇺🇸
Beverly Hills Cancer Center, Beverly Hills, California, United States
🇺🇸The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center, Houston, Texas, United States
A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19
- First Posted Date
- 2020-09-18
- Last Posted Date
- 2021-08-26
- Lead Sponsor
- Noxopharm Limited
- Target Recruit Count
- 41
- Registration Number
- NCT04555213
- Locations
- 🇲🇩
Institute of Emergency Medicine, Chisinau, Moldova, Republic of
A Study of Safety and Tolerability of NOX66 in Healthy Volunteers
Phase 1
Withdrawn
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-05-28
- Lead Sponsor
- Noxopharm Limited
- Registration Number
- NCT03780465
- Locations
- 🇦🇺
Nucleus Network Ltd, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next
News
No news found